Human DDX58 (RIG-I) knockout A549 cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
DDX58 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 16 bp deletion in exon2 and 5 bp deletion in exon2 and 8 bp deletion in exon2.
View Alternative Names
DDX58_HUMAN, DEAD (Asp Glu Ala Asp) box polypeptide 58, DEAD (Asp Glu Ala Asp/His) box polypeptide, DEAD box protein 58, DEAD/H (Asp Glu Ala Asp/His) box polypeptide RIG1, DKFZp434J1111, DKFZp686N19181, FLJ13599, Probable ATP-dependent RNA helicase DDX58, RIG-I, RLR 1, RNA helicase, RNA helicase RIG I, Retinoic acid-inducible gene 1 protein, Retinoic acid-inducible gene I protein, Rig-1, SGMRT2
- WB
Lab
Western blot - Human DDX58 (RIG-I) knockout A549 cell lysate (AB257917)
Lane 1 : Wild-type A549 cell lysate 20 ug
Lane 2 : DDX58 knockout A549 cell lysate 20 ug
Lanes 1 - 2 : Merged signal (red and green). Green - ab180675 observed at 107 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) observed at 55kDa.
ab180675 was shown to react with DDX58 in wild-type A549 cells in western blot with loss of signal observed in DDX58 knockout cell line ab267117 (DDX58 knockout cell lysate ab257917). Wild-type and DDX58 knockout A549 cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3% milk in TBS-T (0.1% Tween®) before incubation with ab180675 and ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4°C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively.. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-RIG-I/DDX58 antibody [EPR18629] (<a href='/en-us/products/primary-antibodies/rig-i-ddx58-antibody-epr18629-ab180675'>ab180675</a>) at 1/1000 dilution
Lane 1:
Wild-type A549 cell lysate at 20 µg
Lane 2:
DDX58 knockout A549 cell lysate at 20 µg
Lane 2:
Western blot - Human DDX58 (RIG-I) knockout A549 cell line (<a href='/en-us/products/cell-lines/human-ddx58-rig-i-knockout-a549-cell-line-ab267117'>ab267117</a>)
Predicted band size: 107 kDa
Observed band size: 107 kDa
false
- Sanger seq
Unknown
Sanger Sequencing - Human DDX58 (RIG-I) knockout A549 cell lysate (AB257917)
Allele-3 : 5 bp deletion in exon2
- Sanger seq
Unknown
Sanger Sequencing - Human DDX58 (RIG-I) knockout A549 cell lysate (AB257917)
Allele-1 : 16 bp deletion in exon2
- Sanger seq
Unknown
Sanger Sequencing - Human DDX58 (RIG-I) knockout A549 cell lysate (AB257917)
Allele-2 : 8 bp deletion in exon2
Reactivity data
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
RIG-I contributes significantly to the innate immune response. It acts to sense viral RNA and triggers the production of type I interferons and other pro-inflammatory cytokines. This protein functions as part of a complex that includes MAVS (mitochondrial antiviral signaling protein) and other signaling adapters. Upon activation RIG-I undergoes a conformational change leading to the exposure of its CARDs which interact with CARDs of MAVS facilitating downstream signaling to induce an antiviral state in host cells.
Pathways
RIG-I plays a central role in the RNA sensing pathway critical for antiviral immunity. This pathway involves several steps beginning with the recognition of viral RNA leading to the activation of interferon regulatory factors like IRF3 and IRF7 as well as nuclear factor kappa B (NF-κB). These factors then promote the expression of interferon-stimulated genes (ISGs). RIG-I also relates closely to the Jak-STAT signaling pathway which is activated by interferons and enhances the transcription of ISGs further amplifying the antiviral response.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Complementary Products
Primary Antibodies
AB180675
Anti-RIG-I/DDX58 antibody [EPR18629]
RabMAb|Recombinant|KO Validated
![Western blot - Anti-RIG-I/DDX58 antibody [EPR18629] (AB180675)](https://content.abcam.com/products/images/rig-i-ddx58-antibody-epr18629-ab180675--western-blot-img164148.jpg)
- 4
- 1
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com